Crescita Therapeutics is set to report its earnings soon, and investors should pay close attention to the context surrounding this low-coverage company.
Crescita Therapeutics Inc (CTX.TO) will release its earnings report for the fiscal period ending June 30, 2026, on August 5, 2026. This report comes at a crucial time for the company, which has faced challenges and changes in recent months. With low analyst coverage and no consensus on expected earnings, investors need to consider the broader business context and recent developments.
Recent earnings trend
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Crescita Therapeutics Inc
CTX.TO
CTX.TO
Crescita Therapeutics Inc
WealthAwesomeMarket cap
$14.71M
52W high
$0.79
52W low
$0.40
1W change
+0.00%
Beta
-0.14
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CTX's historical volatility
30-Day Vol
16.4%
Annualized
90-Day Vol
80.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.94
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.84 | C$0.79 – C$0.89 |
| 60 trading days | C$0.89 | C$0.82 – C$0.96 |
| 90 trading days | C$0.94 | C$0.86 – C$1.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: Low — no EPS consensus estimates are available for this name. Focus on reported EPS trends below rather than beat/miss framing.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | -0.0623 | — | — |
| 2025-12-31 | 2026-03-30 | -0.0382 | — | — |
| 2025-09-30 | 2025-11-12 | 0.0399 | — | — |
| 2025-06-30 | 2025-08-13 | 0.0419 | — | — |
| 2025-03-31 | 2025-05-14 | -0.0490 | — | — |
| 2024-12-31 | 2025-03-11 | -0.0085 | — | — |
Advertisement
Investor takeaway: While Crescita's upcoming earnings report may not provide clear guidance due to the lack of analyst estimates, understanding recent business developments and historical performance can help investors navigate their positions.
Market Cap: CA$14.7 Million, EPS (TTM): -CA$0.01
With a market cap of just CA$14.7 million and a trailing twelve-month EPS of -CA$0.01, Crescita remains a small player in the pharmaceutical sector, making it vulnerable to market fluctuations.
Bull case
The recent acquisition by ClinActiv Holdings could give Crescita additional resources and strategic direction, which may improve its financial outlook in the coming quarters.
Bear case
Crescita's history of net losses and limited analyst coverage raises concerns about its financial stability and ability to generate sustainable profits, which could negatively impact investor sentiment.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
